ADJUVANT PUBLICATIONS & ABSTRACTS
Adjuvant data
Evidence / Adjuvant
Leveraging Real-World Evidence To Personalize Adjuvant Therapy in HR+/HER2- Early Breast Cancer
Publication: JNCI Cancer Spectrum, 2025, 9(5), pkaf092Authors: Yael Bar, MD, PhD , Steven J. Isakoff , MD, PhD , Seth A. Wander , MD, PhDTitle: Leveraging real-world evidence to personalize adjuvant therapy in HR+/HER2- early breast cancerAbstract:The use of gene expression assays (GEAs) to assess the risk of recurrence and Read More
MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data
Publication: JNCI Cancer Spectrum, August 2025 Authors: Brufsky et al. Title: MammaPrint Predicts Chemotherapy Benefit in HR+HER2- Early Breast Cancer: FLEX Registry Real-World Data Abstract Background: Gene expression assays help personalize adjuvant chemotherapy decisions for hormone receptor-positive, HER2-negative (HR+HER2-) early breast cancer (EBC). The 70-gene risk of distant-recurrence signature, MammaPrint, Read More
Real-World Evidence From FLEX: Utility of MammaPrint in Guiding Treatment Planning for Patients Aged 70 and Older With Early-Stage Breast Cancer
Publication: ASCO® 2025 Authors: Reshma Mahtani, Ana Sandoval-Leon, Anna Schrieber, Cathy Graham, Lauren Carcas, Naomi Dempsey, Victoria Poillucci, Michelle Landon, Christa Dreezen, William Audeh Title: Real-world Evidence from FLEX: Utility of MammaPrint in guiding treatment planning for patients aged 70 and older with early-stage breast cancer Background: Older women Read More
Survival Outcomes for Patients With Invasive Lobular Cancer by MammaPrint: Results From the MINDACT Phase III Trial
Publication: European Journal of Cancer 217 (2025) 115222 Authors: O. Metzger Filho, F. Cardoso, C. Poncet, C. Desmedt, S. Linn, J. Wesseling,F. Hilbers, S. Delaloge, J.-Y. Pierga, E. Brain, S. Vrijaldenhoven, P.A. Neijenhuisj, E.J.Th Rutgers, M. Piccart, L.J. van ’t Veerl, G. Viale Title: Survival outcomes for patients with Read More
Prediction of Chemotherapy Benefit by MammaPrint in HR+HER2- Early Stage Breast Cancer Revealed by the FLEX Registry of Real World Data
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky*, Kent Hoskins, Henry Conter, Pond Kelemen, Mehran Habibi, Laila Samian, Robert Maganini, Rakshanda Rahman, Laura Lee, Eduardo Dias, Regina Hampton, Beth Seiling, Cynthia Osborne, Eric Brown, Jailan Elayoubi, Priyanka Sharma, Jayanthi Ramadurai, Laurie Matt-Amral, Alfredo Santillan, Sasha Strain, Philip Albaneze, Read More
Association of MammaPrint With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition
Source: San Antonio Breast Cancer Symposium® Authors: Adam Brufsky, VK Gadi, Aisha Ahmed, Preethi John, Beth Seiling, Josien Haan6, Harshini Ramaswamy, Nicole Stivers, Andrea Menicucci, William Audeh, Joyce O’Shaughnessy, FLEX Investigators’ Group Title: Association of MammaPrint® With Gene Expression Pathways Predictive of Resistance to Cyclin-Dependent Kinase Inhibition Background: Cyclin-dependent kinase Read More
70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up study
Title: 70‑Gene signature‑guided adjuvant systemic treatment adjustments in early‑stage ER+ breast cancer patients: 7‑year follow‑up of a prospective multicenter cohort study Publication: Breast Cancer Research and Treatment 2024 Authors: Eline E. F. Verreck, Anne Kuijer, Julia E. C. van Steenhoven, José H. Volders, Annette W. G. van der Velden, Read More
